MGFA 与 生物新闻o 特色 重症肌无力新闻 在我们的网站上发布资讯，为社区提供研究进展、疾病管理见解和相关新闻。所有内容均为原创，由Bionews编辑团队制作，并包含患者和护理人员的观点。这些信息并非旨在替代或提供医疗建议。
重症肌无力新闻 – 重症肌无力新闻网络每日资源
- The dynamics of writing about my life with myasthenia gravis
by 莎拉·本迪夫 28年2026月2日晚上00:XNUMXWriting this column is the best job I’ve ever had. It gives me the chance to cry my heart out every week about a situation that nobody around me truly understands. I can have a peaceful exchange with complete strangers about a chronic problem we have in common: myasthenia gravis (MG). I’ve explained in the The post The dynamics of writing about my life with myasthenia gravis appeared first on Myasthenia Gravis News.
- Vyvgart tied to symptom relief, corticosteroid reductions in gMG study
by Patricia Inacio 博士 28年2026月12日晚上30:XNUMXTreatment with Vyvgart (efgartigimod) was associated with rapid and sustained symptom easing, lower corticosteroid use, and no unexpected safety concerns in a small real-world study of adults with generalized myasthenia gravis (gMG). The findings suggest the therapy may be a useful option in individualized treatment plans, although larger, longer-term studies are needed to confirm its The post Vyvgart tied to symptom relief, corticosteroid reductions in gMG study appeared first on Myasthenia Gravis News.
- Data from late-stage gMG cell therapy trial expected in early 2027
by 玛丽莎·韦克斯勒女士 27年2026月12日晚上00:XNUMXTop-line results from a global, late-stage clinical trial testing the experimental cell therapy Descartes-08 against a placebo in adults with generalized myasthenia gravis (gMG) are expected in the first months of 2027. The Phase 3 study, AURORA (NCT06799247), aims to enroll about 100 adults with gMG who test positive for self-reactive antibodies targeting the acetylcholine The post Data from late-stage gMG cell therapy trial expected in early 2027 appeared first on Myasthenia Gravis News.
- Intravenous corticosteroids raise risk of sudden symptom spikes in bulbar MG
by 安德烈亚·洛博 26年2026月4日晚上30:XNUMXMore than half of myasthenia gravis (MG) patients with bulbar symptoms, or difficulties swallowing, chewing, and/or speaking, experience a disease exacerbation shortly after starting corticosteroid treatment, according to a study in China. The risk for early exacerbation, or sudden symptom worsening, was found to be significantly higher among patients treated with intravenous (into-the-vein) corticosteroids than The post Intravenous corticosteroids raise risk of sudden symptom spikes in bulbar MG appeared first on Myasthenia Gravis News.
- Sometimes, listening to my body means not blaming everything on MG
by 肖娜·巴恩斯 25年2026月2日晚上00:XNUMXI’m sitting in an infusion chair with saline slowly dripping into my veins after getting a dose of iron, and all I can think is that I spent a full year blaming myasthenia gravis (MG) for this level of exhaustion. For an entire year, I dragged myself through days that felt like wet cement, assuming The post Sometimes, listening to my body means not blaming everything on MG appeared first on Myasthenia Gravis News.
** MGFA 免责声明 – 请阅读
美国重症肌无力基金会 (MGFA) 和 Bionews, Inc.（具体为重症肌无力新闻）已达成有限协议，允许 MGFA 在 myasthenia.org 网站上发布重症肌无力新闻的链接。重症肌无力新闻是一个数字平台，旨在为重症肌无力 (MG) 社区提供有关 MG 的最新新闻和信息，以及来自患者和护理人员专栏作家的第一手社区观点。重症肌无力新闻上的所有文章均为内部作家和编辑撰写的原创内容。偶尔，Bionews 会征求外部专家的意见，进行采访和问答。
重症肌无力新闻的出版团队由科学作家和编辑组成，其中大多数拥有生命科学博士学位；资深记者；以及重症肌无力社区的专栏作家。他们共同努力，确保重症肌无力新闻上发布的所有内容都具有相关性、准确性、信息量大、可关联且易于理解。
每篇内容均由 Bionews 撰稿人精心挑选和撰写，以 MG 社区为中心。新闻报道和资源页面的来源包括同行评审的研究、新闻稿、公告、访谈、网络研讨会和会议等。所有文章都经过严格的事实核查和编辑程序，这是 Bionews 流程的一部分，以确保其准确、客观、全面且解释清楚。
专栏由重症肌无力患者和护理人员撰写，他们深入剖析了身患重症肌无力的生活。虽然专栏主要是观点和看法，但每篇专栏仍经过 Bionews 编辑的全面编辑和事实核查，以确保清晰、准确和公正。
重症肌无力新闻网站是一个专门介绍该疾病的新闻和信息的网站。它不提供医疗建议、诊断或治疗。本内容并非旨在替代专业医疗建议、诊断或治疗。如果您对医疗状况有任何疑问，请务必咨询有执照的医生或其他合格的医疗服务提供者。切勿因为在本网站上读到的内容而忽视专业医疗建议或延迟寻求专业医疗建议。所提供的信息仅供教育之用，不能替代专业医疗建议。
内容反映了作者的独特经历，不一定代表 MGFA 的意见、观点或建议。与 MGFA 相关或合作的医疗顾问和临床医生不会对发布在重症肌无力新闻平台或网站上的文章和信息进行同行评审。MGFA 不对发布在重症肌无力新闻网站上的任何信息、意见、文章、建议、指导或详细信息负责。MGFA 已将此平台发布为 MG 社区服务。请咨询您的医生和医疗保健专业人员，以获取与您的医疗保健/治疗有关的具体建议和意见。